AU781066B2 - Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof - Google Patents

Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof Download PDF

Info

Publication number
AU781066B2
AU781066B2 AU37028/01A AU3702801A AU781066B2 AU 781066 B2 AU781066 B2 AU 781066B2 AU 37028/01 A AU37028/01 A AU 37028/01A AU 3702801 A AU3702801 A AU 3702801A AU 781066 B2 AU781066 B2 AU 781066B2
Authority
AU
Australia
Prior art keywords
group
chelating agent
metal chelating
butyl group
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU37028/01A
Other languages
English (en)
Other versions
AU3702801A (en
Inventor
Avinash N. Amin
Michael G. Douglas
Jose A. Fernandez-Pol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novactyl Inc
Original Assignee
Novactyl Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novactyl Inc filed Critical Novactyl Inc
Publication of AU3702801A publication Critical patent/AU3702801A/en
Application granted granted Critical
Publication of AU781066B2 publication Critical patent/AU781066B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
AU37028/01A 2000-02-15 2001-02-15 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof Ceased AU781066B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18260800P 2000-02-15 2000-02-15
US60/182608 2000-02-15
PCT/US2001/004897 WO2001060349A2 (en) 2000-02-15 2001-02-15 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.

Publications (2)

Publication Number Publication Date
AU3702801A AU3702801A (en) 2001-08-27
AU781066B2 true AU781066B2 (en) 2005-05-05

Family

ID=22669217

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37028/01A Ceased AU781066B2 (en) 2000-02-15 2001-02-15 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof

Country Status (10)

Country Link
US (1) US6403618B1 (cg-RX-API-DMAC7.html)
EP (1) EP1257262A2 (cg-RX-API-DMAC7.html)
JP (1) JP2003522786A (cg-RX-API-DMAC7.html)
AU (1) AU781066B2 (cg-RX-API-DMAC7.html)
BR (1) BR0108400A (cg-RX-API-DMAC7.html)
DE (1) DE01909253T1 (cg-RX-API-DMAC7.html)
ES (1) ES2215493T1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02007954A (cg-RX-API-DMAC7.html)
TR (1) TR200301378T3 (cg-RX-API-DMAC7.html)
WO (1) WO2001060349A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074063A1 (en) * 1995-12-29 2006-04-06 Fernandez-Pol Jose A Pharmacological agent and method of treatment
US6579891B1 (en) * 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
CA2456269A1 (en) * 2001-08-23 2003-03-06 The Government Of The United States Of America Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives
AU2002367087A1 (en) * 2001-12-21 2003-07-15 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
CN101134119A (zh) * 2002-05-24 2008-03-05 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US20050158356A1 (en) * 2003-11-20 2005-07-21 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
CA2552607C (en) * 2004-01-07 2012-04-17 E-L Management Corporation Cosmetic composition and method for retarding hair growth
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
US20070178062A1 (en) * 2005-10-07 2007-08-02 Nathan Ravi Treatment of presbyopia with picolinic acid and its analogs
JP2009512454A (ja) * 2005-10-20 2009-03-26 ビアメト ファーマシューティカルズ,インク. 金属タンパク質のメタル化経路のモジュレーターのスクリーニング方法
EP2482807A4 (en) 2009-10-02 2013-04-24 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS OF CONTACT DERMATITIS
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
WO2018022823A1 (en) * 2016-07-28 2018-02-01 Asieris Pharmaceutical Technologies Co., Ltd. Uses of dopamine beta-hydroxylase (dbh) inhibitors and serotonin receptor (5-ht) antagonists for the treatment of cancer
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds
WO2026104587A1 (en) 2024-11-13 2026-05-21 Adjutec Pharma As Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057320A (en) * 1988-08-01 1991-10-15 Nutrition 21 Means and method for increasing skin respiration
US5219847A (en) * 1989-06-12 1993-06-15 Shiseido Company, Ltd. Antipruritic composition
WO1997024121A1 (en) * 1995-12-29 1997-07-10 Fernandez Pol Jose A Antiviral agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903285A (en) 1972-12-29 1975-09-02 Microbial Chem Res Found Method for treating parkinsonism
CH629488A5 (en) 1975-11-28 1982-04-30 Scherico Ltd Processes for preparing novel picolinic acid derivatives.
ZA767103B (en) 1975-11-28 1977-10-26 Scherico Ltd Picolinic acid derivatives and processes for their preparation
US4044140A (en) 1975-11-28 1977-08-23 Schering Corporation Trityl picolinic acid derivatives and their use as anti-acne agents
US4120762A (en) 1977-09-30 1978-10-17 Alden Research Foundation Electrochemical recording medium
US4293547A (en) 1980-08-25 1981-10-06 The Upjohn Company Method of treating malaria
US4443459A (en) 1981-05-26 1984-04-17 Banyu Pharmaceutical Co., Ltd. α-Tocopheryl ester of 5-substituted picolinic acid and hypotensive composition containing it
US4814351A (en) 1987-06-26 1989-03-21 Redken Laboratories, Inc. Scalp treatment
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5157046A (en) 1988-11-29 1992-10-20 Janssen Pharmaceutica N.V. Method of treating epithelial disorders
FR2657259A1 (fr) 1990-01-25 1991-07-26 Adir Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5391537A (en) 1990-10-25 1995-02-21 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative, and herbicidal composition
US5403816A (en) 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
US5173486A (en) 1991-08-26 1992-12-22 Bristol-Myers Squibb Company Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
IL104323A0 (en) 1992-01-10 1993-05-13 Smithkline Beecham Corp Hemoregulatory peptides
US5284840A (en) 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5962463A (en) * 1992-10-09 1999-10-05 Massachusetts Institute Of Technology Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein
AU7044994A (en) 1993-05-24 1994-12-20 Nycomed Pharma Hemoregulatory peptides
US6001555A (en) 1994-09-23 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein
FR2736263B1 (fr) 1995-07-07 1997-09-26 C3D Sarl Composition dermocosmetique depigmentante et son utilisation
JP3337992B2 (ja) 1997-11-04 2002-10-28 ファイザー製薬株式会社 5−置換ピコリン酸化合物及びその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057320A (en) * 1988-08-01 1991-10-15 Nutrition 21 Means and method for increasing skin respiration
US5219847A (en) * 1989-06-12 1993-06-15 Shiseido Company, Ltd. Antipruritic composition
WO1997024121A1 (en) * 1995-12-29 1997-07-10 Fernandez Pol Jose A Antiviral agent

Also Published As

Publication number Publication date
EP1257262A2 (en) 2002-11-20
MXPA02007954A (es) 2004-09-10
DE01909253T1 (de) 2004-04-15
JP2003522786A (ja) 2003-07-29
US6403618B1 (en) 2002-06-11
AU3702801A (en) 2001-08-27
TR200301378T3 (tr) 2003-12-22
BR0108400A (pt) 2003-03-11
WO2001060349A3 (en) 2001-11-08
WO2001060349A2 (en) 2001-08-23
WO2001060349B1 (en) 2001-12-27
ES2215493T1 (es) 2004-10-16

Similar Documents

Publication Publication Date Title
US6410570B1 (en) Methods of inactivating a virus and controlling viral replication
US6579891B1 (en) Agent and method for prevention and treatment of cancer in animals
US5767135A (en) Antiviral agent
US6407125B1 (en) Pharmacological agent and method of treatment
US20060074063A1 (en) Pharmacological agent and method of treatment
US6403618B1 (en) Agent and method for controlling angiogenesis
US6803379B2 (en) Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
EP0842660B1 (en) Composition for treating condyloma acuminata
WO2014008248A2 (en) Compositions and methods for treating and inhibiting viral infections
CN116583267A (zh) 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用
US6441009B1 (en) Agent and method of preventing and treating heavy metal exposure and toxicity
US20140011838A1 (en) Compositions and methods for treating warts associated with viral infections
Cutler et al. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus
KR102873848B1 (ko) 백신을 사용하여 암 또는 피부 병변을 치료하기 위한 방법 및 조성물
US20240425493A1 (en) Small molecule antiviral drug treatment for human papillomavirus infections
Tyring Immune-response modifiers: a new paradigm in the treatment of human papillomavirus
US20140011839A1 (en) Compositions and methods for treating and inhibiting viral infections
US20170296530A1 (en) Compositions and Methods for Treating and Inhibiting Viral Infections
US20140011837A1 (en) Compositions and methods for treating warts associated with viral infections
Husseinzadeh Basic therapeutic principles and the strategy in the management of the external anogenital warts (condylomas): A review
WO2022123323A1 (en) A pharmaceutical composition of artesunate and mefloquine and method thereof
WO2005053694A1 (en) Treatment of hpv infections and cancer
US20090247641A1 (en) Hydrazone agents to treat cutaneous lesions
KR101671484B1 (ko) 오셀타미비르(Oseltamivir)를 포함하는 인유두종 바이러스 치료용 약학적 조성물
WO2024255913A1 (zh) 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用